Core Viewpoint - Roche Pharmaceuticals China announced the approval of its innovative antiviral treatment, Sufo Da® dry mixed suspension, by the National Medical Products Administration of China on March 3, 2026, for the treatment of uncomplicated influenza A and B in children aged 1 to under 5 years, including both previously healthy patients and those at high risk for influenza complications [1] Group 1 - The drug is specifically indicated for children aged 1 to under 5 years [1] - The approval expands the treatment options available for young children suffering from influenza [1] - The product targets both uncomplicated cases and those with high-risk complications [1]